
CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase III studies The European Commission is […]
Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase III studies The European Commission is […]
Copyright © 2023 | WordPress Theme by MH Themes